New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

Ferrante, Marc; Henckaerts, Liesbet; Joossens, Marie; Pierik, Marie J.; Joossens, Sofie; Dotan, Nir; Norman, Gary L.; Altstock, Rom T.; Steen, Kristel Van; Rutgeerts, Paul; Assche, Gert Van; Vermeire, Séverine

doi:10.1136/gut.2006.108043

Cited by 274 publications

(284 citation statements)

References 37 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…Biomarkers have also been studied, including antiSaccharomyces cerevisiae antibodies (ASCAs). ASCA seropositivity has been repeatedly associated with need for surgery in CD, but these reports are largely retrospective and confounded by the trend to increasing ASCA titers with time (11,12). Likewise, genetic variants at NOD2 (13) and HLA-DRB1*0103 (14) are statistically associated with need for surgery in CD and UC, respectively, but their poor sensitivity and the low frequency of the *0103 variant precludes their clinical use.…”

Section: Introductionmentioning

confidence: 99%

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

Lee¹,

Lyons²,

McKinney³

et al. 2011

J. Clin. Invest.

283

258

View full text Add to dashboard Cite

Crohn disease (CD) and ulcerative colitis (UC) are increasingly common, chronic forms of inflammatory bowel disease. The behavior of these diseases varies unpredictably among patients. Identification of reliable prognostic biomarkers would enable treatment to be personalized so that patients destined to experience aggressive disease could receive appropriately potent therapies from diagnosis, while those who will experience more indolent disease are not exposed to the risks and side effects of unnecessary immunosuppression. Using transcriptional profiling of circulating T cells isolated from patients with CD and UC, we identified analogous CD8 + T cell transcriptional signatures that divided patients into 2 otherwise indistinguishable subgroups. In both UC and CD, patients in these subgroups subsequently experienced very different disease courses. A substantially higher incidence of frequently relapsing disease was experienced by those patients in the subgroup defined by elevated expression of genes involved in antigen-dependent T cell responses, including signaling initiated by both IL-7 and TCR ligation -pathways previously associated with prognosis in unrelated autoimmune diseases. No equivalent correlation was observed with CD4 + T cell gene expression. This suggests that the course of otherwise distinct autoimmune and inflammatory conditions may be influenced by common pathways and identifies what we believe to be the first biomarker that can predict prognosis in both UC and CD from diagnosis, a major step toward personalized therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

Lee¹,

Lyons²,

McKinney³

et al. 2011

J. Clin. Invest.

283

258

View full text Add to dashboard Cite

show abstract

“…[19][20][21][22][23][24] These panels include antibodies directed at several microbial antigens including oligomannan (anti-Saccharomyces cerevisiae or ASCA), Escherichia coli outer membrane porin C (anti-OmpC), flagellin (anti-CBir1), antilaminaribioside (ALCA), antimannobioside (AMCA), antichitobioside (ACCA), antichitin (anti-C), and antilaminarin (anti-L). 21,[25][26][27][28][29][30] The clinical utility of these panels is an area of ongoing interest, but their greatest potential may lie in their predictive capacity (for a more detailed review see the article by Rubin in this issue).…”

Section: The Challenge Of Choosing the Appropriate Therapy For The Nementioning

confidence: 99%

Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up

Devlin

Panaccione

2009

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

“…Crohn's disease (CD) is an interesting topic for transversal research, since this chronic inflammatory bowel disease is generally agreed to be triggered by genetic susceptibility to gut microbiota (11). As the development of CD has also been linked to the sequential appearance of antibodies against microbial antigens (13,23), we investigated whether anti-C. albicans antibodies were associated with this disease. Antibodies against Saccharomyces cerevisiae mannan (ASCA) are widely used as serological markers of CD (47).…”

mentioning

confidence: 99%

Antibodies against Glucan, Chitin, and Saccharomyces cerevisiae Mannan as New Biomarkers of Candida albicans Infection That Complement Tests Based on C. albicans Mannan

Sendid

Dotan²,

Nseir

et al. 2008

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Antibodies against Saccharomyces cerevisiae mannan (ASCA) and antibodies against synthetic disaccharide fragments of glucans (ALCA) and chitin (ACCA) are biomarkers of Crohn's disease (CD). We previously showed that Candida albicans infection generates ASCA. Here, we explored ALCA and ACCA as possible biomarkers of invasive C. albicans infection (ICI). ASCA, ALCA, ACCA, and Candida mannan antigen and antibody detection tests were performed on 69 sera obtained sequentially from 18 patients with ICIs proven by blood culture, 59 sera from CD patients, 47 sera from hospitalized subjects colonized by Candida species (CZ), and 131 sera from healthy controls (HC). ASCA, ALCA, and ACCA levels in CD and ICI patients were significantly different from those in CZ and HC subjects (P < 0.0001). In ICI patients, these levels increased as infection developed. Using ASCA, ALCA, ACCA, and Platelia Candida tests, 100% of ICIs were detected, with the kinetics of the antibody response depending on the patient during the time course of infection. A large number of sera presented with more than three positive tests. This is the first evidence that the detection of antibodies against chitin and glucans has diagnostic value in fungal infections and that these tests can complement more specific tests. Future trials are necessary to assess the value of these tests in multiparametric analysis, as well as their pathophysiological relevance.

show abstract

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

Cited by 274 publications

References 37 publications

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up

Antibodies against Glucan, Chitin, and Saccharomyces cerevisiae Mannan as New Biomarkers of Candida albicans Infection That Complement Tests Based on C. albicans Mannan

Contact Info

Product

Resources

About